Xin Lang Cai Jing·2025-11-23 09:36Group 1: IPO Market Overview - Since 2025, the Hong Kong stock market has seen 86 new IPOs, raising approximately 2508.84 million HKD [1] - In the past week (November 16 to November 22), there was 1 listing, 3 companies in the IPO process, 4 companies undergoing hearings, and 6 companies that submitted applications [1][2] - The average issuance market value of the last 10 new listings is 631.20 million HKD, with an average PE ratio of 28.72 [23] Group 2: Recent IPOs - Zhongwei New Materials (2698.HK) successfully listed on the Hong Kong Stock Exchange on November 17, with a first-day closing price down 0.12% and a total market value of 353.95 million HKD [4][3] - The stock price of Zhongwei New Materials has dropped 16% in its first week of trading [1] - The average first-day increase for recent IPOs is 40.38%, indicating a cooling trend in the AH new stock market [23] Group 3: Upcoming IPOs - Three companies, including Innovation Industry, Quantitative Group, and Haiwei Co., are currently in the IPO process, with expected listing dates between November 24 and November 28, 2025 [5][9] - Innovation Industry completed its IPO with a subscription ratio exceeding 3600 times, indicating strong investor interest [8] - Haiwei Co. has a subscription ratio exceeding 800 times as of November 23, 2025 [10] Group 4: Companies Undergoing Hearings - Four companies passed hearings in the past week, including Naxin Microelectronics, LeMo Technology, Yujian Xiaomian, and Jinyan High-tech [11][12][13][15] - Naxin Microelectronics reported a revenue of 1.524 billion RMB in the first half of 2025, with a year-on-year growth of 80% [11] - LeMo Technology's revenue for 2024 was nearly 800 million RMB, with a growth of 36% [12] Group 5: Companies Submitting Applications - Six companies submitted applications to the Hong Kong Stock Exchange, including Liying Intelligent Manufacturing, Mandi International, and others [16] - Liying Intelligent Manufacturing reported a revenue of 44.26 billion RMB in 2024, with a year-on-year growth of nearly 30% [17] - Mandi International, a spin-off from Sanofi Pharmaceutical, reported a revenue of 1.455 billion RMB in 2024, with a growth of nearly 20% [18]